

***Fiscal Year 2020 Duchenne Muscular Dystrophy Research Program (DMDRP)
Reference Table of Award Mechanism and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadlines
<p>Idea Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-20-DMDRP-IDA</p>	<p>Principal Investigator (PI): Independent investigators at all academic levels (or equivalent).</p>	<ul style="list-style-type: none"> • Supports the development of innovative, high-impact ideas that advance the understanding of Duchenne muscular dystrophy (DMD) and ultimately lead to improved outcomes. • Must address opportunities and challenges in the development of safe and effective macromolecular and cellular therapies that address primary pathology of DMD. Eligible therapeutic strategies include: gene therapy, genome editing, oligonucleotide therapies, exon skipping, protein therapeutics, and cell therapies. <i>Therapies that will be efficacious across the life-span, particularly in adolescents and adults are encouraged.</i> • Clinical trials are not allowed. • Preliminary data are required. 	<ul style="list-style-type: none"> • Maximum funding of \$350,000 for direct costs (plus indirect costs). • Maximum period of performance is 2 years 	<p>Pre-Application: August 12, 2020 5:00 p.m. Eastern time</p> <p>Preproposal is required; application submission is by invitation only.</p> <p>Application: December 7, 2020 11:59 p.m. Eastern time</p>
<p>Translational Research Partnership Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-20-DMDRP-TRPA</p>	<p>Principal Investigator (PI): Investigators at or above the level of Assistant Professor (or equivalent).</p>	<ul style="list-style-type: none"> • Supports the development of translational research collaborations between two independent investigators to address a critical problem or question in DMD and to accelerate the movement of promising ideas into clinical application. • Partnerships where one partner in the collaboration is a research scientist and the other is a clinician are <i>strongly encouraged</i>. • <i>Must</i> address one of the FY20 Translational Research Partnership Award Focus Areas • Clinical trials are allowed. • Preliminary data are required. 	<ul style="list-style-type: none"> • Maximum combined funding of \$1,200,000 for direct costs (plus indirect costs). • Maximum period of performance is 3 years 	<p>Pre-Application: August 12, 2020 5:00 p.m. Eastern time</p> <p>Preproposal is required; application submission is by invitation only.</p> <p>Application: December 7, 2020 11:59 p.m. Eastern time</p>